KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Receivables (2017 - 2025)

Aquestive Therapeutics has reported Change in Receivables over the past 9 years, most recently at $6.0 million for Q4 2025.

  • Quarterly results put Change in Receivables at $6.0 million for Q4 2025, up 356.63% from a year ago — trailing twelve months through Dec 2025 was $10.4 million (up 1048.08% YoY), and the annual figure for FY2025 was $10.4 million, up 1048.08%.
  • Change in Receivables for Q4 2025 was $6.0 million at Aquestive Therapeutics, up from -$63000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for AQST hit a ceiling of $7.7 million in Q1 2022 and a floor of -$8.2 million in Q3 2022.
  • Median Change in Receivables over the past 5 years was $635500.0 (2021), compared with a mean of $517600.0.
  • Biggest five-year swings in Change in Receivables: tumbled 2132.69% in 2024 and later skyrocketed 2228.57% in 2025.
  • Aquestive Therapeutics' Change in Receivables stood at -$1.4 million in 2021, then tumbled by 343.92% to -$6.1 million in 2022, then skyrocketed by 98.29% to -$104000.0 in 2023, then tumbled by 2132.69% to -$2.3 million in 2024, then skyrocketed by 356.63% to $6.0 million in 2025.
  • The last three reported values for Change in Receivables were $6.0 million (Q4 2025), -$63000.0 (Q3 2025), and $1.3 million (Q2 2025) per Business Quant data.